Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07654972 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07654972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
June 24, 2026
Completion date
April 30, 2029
Enrollment
108 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight